2015
Update in Diffuse Parenchymal Lung Disease 2013
Rosas IO, Kaminski N. Update in Diffuse Parenchymal Lung Disease 2013. American Journal Of Respiratory And Critical Care Medicine 2015, 191: 270-274. PMID: 25635490, PMCID: PMC4351573, DOI: 10.1164/rccm.201405-0856up.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Inflammatory Agents, Non-SteroidalClinical Trials, Phase III as TopicDisease ProgressionDrug ApprovalEnzyme InhibitorsGenomicsHumansIdiopathic Pulmonary FibrosisIndolesLung Diseases, InterstitialPolymorphism, GeneticPyridonesTreatment OutcomeUnited StatesUnited States Food and Drug AdministrationConceptsMajority of patientsDistinct clinical presentationsSignificant clinical implicationsClinical presentationPulmonary fibrosis researchDisease progressionClinical implicationsGenetic biomarkersPatientsFibrosis researchGenetic variantsBiological mechanismsIPFNew biological mechanismsNintedanibPirfenidonePeriodHistoric approval
2013
Association Between the MUC5B Promoter Polymorphism and Survival in Patients With Idiopathic Pulmonary Fibrosis
Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, Silveira LJ, Lindell KO, Steele MP, Loyd JE, Gibson KF, Seibold MA, Brown KK, Talbert JL, Markin C, Kossen K, Seiwert SD, Murphy E, Noth I, Schwarz MI, Kaminski N, Schwartz DA. Association Between the MUC5B Promoter Polymorphism and Survival in Patients With Idiopathic Pulmonary Fibrosis. JAMA 2013, 309: 2232-2239. PMID: 23695349, PMCID: PMC4545271, DOI: 10.1001/jama.2013.5827.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisChicago cohortPulmonary fibrosisImproved survivalPromoter polymorphismInterstitial lung disease clinicMUC5B Promoter PolymorphismPrimary end pointNumber of patientsTT genotype groupCommon risk polymorphismsChicago patientsIPF mortalityMedian followCause mortalityCumulative incidenceMechanisms of diseaseDisease clinicRetrospective studyVital capacityClinical trialsBlood concentrationsClinical covariatesMAIN OUTCOMETreatment status
2012
Allele-specific transactivation of matrix metalloproteinase 7 by FOXA2 and correlation with plasma levels in idiopathic pulmonary fibrosis
Richards TJ, Park C, Chen Y, Gibson KF, Di Y, Pardo A, Watkins SC, Choi AM, Selman M, Pilewski J, Kaminski N, Zhang Y. Allele-specific transactivation of matrix metalloproteinase 7 by FOXA2 and correlation with plasma levels in idiopathic pulmonary fibrosis. American Journal Of Physiology - Lung Cellular And Molecular Physiology 2012, 302: l746-l754. PMID: 22268124, PMCID: PMC3331579, DOI: 10.1152/ajplung.00319.2011.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisMatrix metalloproteinase-7Plasma levelsIPF patientsPulmonary fibrosisMetalloproteinase-7MMP7 promoterIPF cohortIPF lungsPeripheral bloodHealthy controlsEmbryonic lung developmentPromoter polymorphismAA genotypeCT genotypeForkhead box A2 transcription factorMature lungLung developmentLungEpithelial cellsRs11568818PatientsFibrosisUpregulationKey regulator